Global Investment Research-New York- Associate Research Analyst-9206936

Goldman Sachs•New York, NY

18h•$150,000 - $194,000•Onsite

About The Position

The Associate Research Analyst will prepare technical and research reports evaluating drug pipelines through the analysis of preclinical and clinical data. This role involves conducting technical analyses on biology-based research programs, developing clinical trial statistical models and analyses, and delving into intellectual property and litigation as it relates to drug development and commercialization in biotechnology and pharmaceuticals. The analyst will also attend biomedical conferences and speak with key opinion leaders to assess cutting-edge breakthroughs in biology and drug development. Additionally, they will review biological and scientific journals, write research reports on their findings, and evaluate advanced scientific topics on disease biological pathways and pathological mechanisms of action of drug modalities across various therapeutic areas. The role requires analyzing drug mechanisms and their effects on disease pathways, efficacy, and patient outcomes by applying expertise in DNA, RNA, antibodies, siRNA, bispecifics, ADCs, and proteins. A key aspect is evaluating molecular properties of drug structures to determine pharmacodynamic and pharmacokinetic properties, including ADME properties. Finally, the analyst will assess drug candidates’ commercial potential by evaluating potential payer management criteria, reimbursement challenges, prescriber receptivity, and patient usage.

Requirements

Bachelor’s degree (U.S. or foreign equivalent) in Biology, Molecular Biology, Neuroscience, Biochemistry, Biotech, or a related field.
Three (3) years of experience in the job offered or in a drug development R&D role within biopharma or consulting companies.
Three (3) years of experience with writing and publishing scientific technical research reports.
Three (3) years of experience conducting analyses on preclinical models, PK/PD, and clinical trial results to evaluate drug pipelines and therapeutic viability.
Three (3) years of experience conducting technical analyses on novel drug development research programs by analyzing biology of drug and disease mechanisms.
Three (3) years of experience developing clinical trial statistical models to assess potential outcomes.
Three (3) years of experience assessing patents and intellectual property considerations in biotechnology and pharmaceuticals.
Three (3) years of experience performing analysis on drug candidates potential to successfully complete FDA’s IND, NDA, BLA, and EMA’s drug evaluation procedures.
One (1) year of experience building financial models of company income statement, balance sheet, cash flow, and market models by drug indications.
SIE, Series 86, 87, and 63 required.

Responsibilities

Prepare technical and research reports evaluating drug pipelines through the analysis of preclinical and clinical data.
Conduct technical analyses on biology-based research programs.
Develop clinical trial statistical models and analyses.
Delve into intellectual property and litigation as it relates to drug development and commercialization in biotechnology and pharmaceuticals.
Attend biomedical conferences and speak with key opinion leaders to assess and evaluate cutting-edge breakthroughs in the field of biology and drug development.
Review biological and scientific journals as they relate to the development of novel drugs, scientific policies, and regulatory and clinical use guidance.
Write research reports on the analyses of findings.
Evaluate a variety of advanced scientific topics on disease biological pathways and pathological mechanisms of action of drug modalities in oncology, gene editing/therapy, viral/infectious, neuroscience, autoimmune, inflammatory, cardiovascular, and obesity/metabolic diseases.
Analyze drug mechanisms and their effects on disease pathways, efficacy, and patient outcomes by applying expertise in the structure and function of DNA, RNA, antibodies, siRNA, bispecifics, ADCs, and proteins to assess the approvability and viability of novel drug development candidates.
Evaluate molecular properties of drug structures to determine their pharmacodynamic and pharmacokinetic properties including brain penetration, metabolic pathways, drug-drug interactions, toxicity, and other ADME properties.
Assess drug candidates’ commercial potential by assessing potential payer management criteria, reimbursement challenges, prescriber receptivity, and patient usage.